Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

unknow

★ 5.0 · 33 reads

Sign in to save this
Request Code
ZLIB.IO18514040
Published
2022
Pages
1
Language
Unknown